CytomX Therapeutics (CTMX) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CytomX Therapeutics is the larger company by market cap ($538.2 million vs $508.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | MPLT |
|---|---|---|
| Share price | $2.47 | $9.15 |
| Market cap | $538.21M | $508.52M |
| 1-day change | -3.14% | -2.24% |
| YTD return | -40.14% | -46.71% |
| 1-year return | -23.42% | — |
| 5-year return | -50.39% | — |
| EPS (TTM) | $-0.51 | $-6.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.21 | $40.43 |
| 52-week low | $2.43 | $8.92 |
| Distance from 52-week high | -69.91% | -77.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +395.95% | +190.05% |
| Average volume | 3.34M | 858.68K |
| Shares outstanding | 217.90M | 52.85M |
| Employees | 69 | 133 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
CTMX vs MPLT FAQ
Which is bigger, CytomX Therapeutics or MapLight Therapeutics?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $538.21M compared with $508.52M for MapLight Therapeutics (MPLT).
Are CytomX Therapeutics and MapLight Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.